Skip to main content
. 2020 Oct 21;11(12):375–378. doi: 10.14740/jmc3584

Table 1. Overview of the Various Series With Multisystemic Inflammatory Syndrome in Children.

Author Toubiana et al, 2020 [9] Whittaker et al, 2020 [10] Feldstein et al, 2020 [11] Davies et al, 2020 [12] Belhadjer et al, 2020 [13]
County France UK USA UK France/Switzerland
Patients 21 58 186 78 35
Median age (year) 7.9 9 8.3 11 10
Male (%) 43 66 62 66 51
KD complet/incomplete (%) 55/NA 22/NA 20.4/19.3 NA -
KDSS (%) 57% - - NA -
Epidemiological contact (%) 48 29.5 NA 37
SARS-CoV-2 positive (%) 90 78 70 64 88.5
Gastrointestinal system (%) 100 45-53 92 90 83
Shock (%) 57 50 NA 87 80
Myocardial dysfunction (%) 76 31 33 NA 72
Neurological system (%) 29 26 7 87 NA
Laboratory findings ↓ Lymphocytes, albumin and serum sodium; ↑ CRP, procalcitonin, ALT, DD, NT-proBNP and IL-6 ↓ Lymphocytes, albumin serum; ↑ CRP, ferritin, neutrophils, troponin I and NT-proBNP ↓ Lymphocytes, albumin serum and platelets; ↑ CRP, neutrophils, ferritin, DD, fibrinogen, troponin I and NT-proBNP, and ALT ↓ Lymphocytes, platelets; ↑ CRP, ferritin, DD and troponin I ↓ Lymphocytes; ↑ CRP, troponin I, ferritin, DD and IL-6
CAA (%) 24 NA NA 36 17
Coronary aneurisms (%) 0 14.5 8 23 0
IVIG (%) 100 71 77 76 71
Second dose IVIG (%) 24 NA 21 NA 2.8
Systemic steroids (%) 48 64 49 73 34
Fluid resuscitation (%) 52 79 NA 92 NA
Vasoactive and inotropic agents (%) 71 47 48 83 80
Mechanical ventilation (%) 52 43 20 46 62
Biologic therapy (%) 0 19 21 22 8
Anticoagulation therapy (%) 0 0 47 50 65
Death (%) 0 2 2 2.5 0

SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; IVIG: intravenous immunoglobulin; KD: Kawasaki disease; KDSS: KD shock syndrome; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; AST: aspartate aminotransferase; ALT: alanine aminotransferase, LDH: lactate dehydrogenase; DD: D-dimer; NT-proBNP: N-terminal pro-brain-type natriuretic peptide; CAA: coronary artery abnormalities; NA: not available; IL: interleukin.